Stock DNA
Pharmaceuticals & Biotechnology
EUR 18 Million ()
NA (Loss Making)
NA
2.99%
-0.34
-0.62%
0.88
Revenue and Profits:
Net Sales:
6 Million
(Quarterly Results - Sep 2022)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
8.06%
0%
8.06%
6 Months
7.72%
0%
7.72%
1 Year
-19.86%
0%
-19.86%
2 Years
-39.64%
0%
-39.64%
3 Years
-41.64%
0%
-41.64%
4 Years
-62.53%
0%
-62.53%
5 Years
-70.35%
0%
-70.35%
Geratherm Medical AG for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.59%
EBIT Growth (5y)
-37.33%
EBIT to Interest (avg)
1.40
Debt to EBITDA (avg)
0.10
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.90
Tax Ratio
100.00%
Dividend Payout Ratio
76.75%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.11%
ROE (avg)
3.35%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.95
EV to EBIT
12.78
EV to EBITDA
6.04
EV to Capital Employed
0.92
EV to Sales
0.53
PEG Ratio
NA
Dividend Yield
2.75%
ROCE (Latest)
1.65%
ROE (Latest)
-0.62%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'22 - QoQ
Sep'22
Jun'22
Change(%)
Net Sales
6.10
5.90
3.39%
Operating Profit (PBDIT) excl Other Income
0.80
0.80
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.20
0.10
100.00%
Operating Profit Margin (Excl OI)
55.70%
54.80%
0.09%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2022 is 3.39% vs -7.81% in Jun 2022
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2022 is 100.00% vs -80.00% in Jun 2022
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
14.00
21.00
-33.33%
Operating Profit (PBDIT) excl Other Income
-3.00
3.40
-188.24%
Interest
0.10
0.20
-50.00%
Exceptional Items
-0.30
0.00
Consolidate Net Profit
0.70
1.70
-58.82%
Operating Profit Margin (Excl OI)
-344.70%
80.90%
-42.56%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -33.33% vs -18.92% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -58.82% vs 54.55% in Dec 2023
About Geratherm Medical AG 
Geratherm Medical AG
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






